AR005930A1 - Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn - Google Patents
Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adnInfo
- Publication number
- AR005930A1 AR005930A1 ARP970100684A ARP970100684A AR005930A1 AR 005930 A1 AR005930 A1 AR 005930A1 AR P970100684 A ARP970100684 A AR P970100684A AR P970100684 A ARP970100684 A AR P970100684A AR 005930 A1 AR005930 A1 AR 005930A1
- Authority
- AR
- Argentina
- Prior art keywords
- vaccine compositions
- dna expression
- hiv genes
- synthetic hiv
- increasing dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proveen moléculas de ADN sintéticas que codifican genes de HIV y modificaciones de genes de HIV. Los codones de las moléculas sintéticas usancodones preferidos para la célula huésped proyectada. Las moléculas sintéticas pueden usarse en forma de una vacuna polinucleotídica que proveeinmunoprofilaxis eficaz contra infección causada por HIV a través de un anticuerpo neutralizador e inmunidad intermediada por células.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1208296P | 1996-02-22 | 1996-02-22 | |
GBGB9607293.9A GB9607293D0 (en) | 1996-04-09 | 1996-04-09 | Synthetic hiv env genes |
Publications (1)
Publication Number | Publication Date |
---|---|
AR005930A1 true AR005930A1 (es) | 1999-07-21 |
Family
ID=26309076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970100684A AR005930A1 (es) | 1996-02-22 | 1997-02-20 | Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn |
Country Status (27)
Country | Link |
---|---|
EP (1) | EP0904380B1 (es) |
JP (1) | JP2000505299A (es) |
KR (1) | KR19990087126A (es) |
CN (1) | CN1216064A (es) |
AR (1) | AR005930A1 (es) |
AT (1) | ATE309366T1 (es) |
AU (1) | AU729231B2 (es) |
BG (1) | BG102784A (es) |
BR (1) | BR9707672A (es) |
CO (1) | CO4600706A1 (es) |
CZ (1) | CZ266798A3 (es) |
DE (1) | DE69734585T2 (es) |
EE (1) | EE9800257A (es) |
ES (1) | ES2251734T3 (es) |
HR (1) | HRP970092A2 (es) |
HU (1) | HUP9901112A3 (es) |
ID (1) | ID16021A (es) |
IL (1) | IL125547A0 (es) |
IS (1) | IS4814A (es) |
NO (1) | NO983876L (es) |
NZ (1) | NZ331161A (es) |
PE (1) | PE43298A1 (es) |
PL (1) | PL328730A1 (es) |
SK (1) | SK112998A3 (es) |
TR (1) | TR199801615T2 (es) |
WO (1) | WO1997031115A2 (es) |
YU (1) | YU35498A (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6534312B1 (en) | 1996-02-22 | 2003-03-18 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
CA2258568A1 (en) * | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Vaccines comprising synthetic genes |
EE9900343A (et) * | 1997-02-07 | 2000-02-15 | Merck & Co., Inc. | Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon |
US6696291B2 (en) | 1997-02-07 | 2004-02-24 | Merck & Co., Inc. | Synthetic HIV gag genes |
US7105724B2 (en) | 1997-04-04 | 2006-09-12 | Board Of Regents Of University Of Nebraska | Methods and materials for making and using transgenic dicamba-degrading organisms |
KR100558838B1 (ko) | 1997-04-04 | 2006-03-10 | 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 | 유전자이식 디캄바-분해 유기체를 제조하고 사용하기 위한 방법 및 물질 |
AU2003200914B2 (en) * | 1997-10-20 | 2007-02-01 | Gtc Biotherapeutics, Inc. | Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems |
CN1179048C (zh) * | 1997-10-20 | 2004-12-08 | Gtc生物治疗学公司 | 修饰的MSP-1核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法 |
GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
US6924365B1 (en) | 1998-09-29 | 2005-08-02 | Transkaryotic Therapies, Inc. | Optimized messenger RNA |
JP2002533124A (ja) * | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Hivポリペプチドの改善された発現およびウイルス様粒子の生成 |
EP1433851A3 (en) * | 1998-12-31 | 2004-10-13 | Chiron Corporation | Improved expression of HIV polypeptides and production of virus-like particles |
EP1535995A1 (en) * | 1998-12-31 | 2005-06-01 | Chiron Corporation | Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US6395714B1 (en) | 1999-02-24 | 2002-05-28 | Aventis Pasteur Limited | Expressing gp140 fragment of primary HIV-1 isolate |
WO2000029561A2 (en) | 1999-03-29 | 2000-05-25 | Statens Serum Institut | Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
US6316253B1 (en) | 1999-11-01 | 2001-11-13 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
AU779951B2 (en) * | 1999-12-22 | 2005-02-24 | Merck & Co., Inc. | Polynucleotide vaccines expressing codon optimized HIV-1 pol and modified HIV-1 pol |
GB0014288D0 (en) | 2000-06-10 | 2000-08-02 | Smithkline Beecham Biolog | Vaccine |
GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
CA2425152A1 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
KR20020059856A (ko) | 2001-01-08 | 2002-07-16 | 김철중 | 에이치아이브이 유사입자의 제조 |
EP1411770A4 (en) | 2001-07-05 | 2006-05-10 | Chiron Corp | POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE |
EP1427826B1 (en) * | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | HIV- RT-nef-Gag codon optimised DNA vaccines |
ATE554106T1 (de) | 2003-12-23 | 2012-05-15 | Arbor Vita Corp | Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung |
US7855326B2 (en) | 2006-06-06 | 2010-12-21 | Monsanto Technology Llc | Methods for weed control using plants having dicamba-degrading enzymatic activity |
EA020590B1 (ru) | 2006-10-16 | 2014-12-30 | Монсанто Текнолоджи Ллс | Способы улучшения жизнеспособности растений |
US7838729B2 (en) | 2007-02-26 | 2010-11-23 | Monsanto Technology Llc | Chloroplast transit peptides for efficient targeting of DMO and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69434469T2 (de) * | 1993-01-26 | 2006-06-14 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
CA2181832C (en) * | 1994-01-27 | 2012-11-27 | Harriet L. Robinson | Immunization by inoculation of dna transcription unit |
US6630455B1 (en) * | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
JPH08198774A (ja) * | 1995-01-20 | 1996-08-06 | Terumo Corp | Dnaワクチン |
-
1997
- 1997-02-18 JP JP9530231A patent/JP2000505299A/ja not_active Ceased
- 1997-02-18 CN CN97193817A patent/CN1216064A/zh active Pending
- 1997-02-18 NZ NZ331161A patent/NZ331161A/xx unknown
- 1997-02-18 WO PCT/US1997/002294 patent/WO1997031115A2/en active IP Right Grant
- 1997-02-18 AT AT97906594T patent/ATE309366T1/de not_active IP Right Cessation
- 1997-02-18 KR KR1019980706517A patent/KR19990087126A/ko not_active Application Discontinuation
- 1997-02-18 AU AU21246/97A patent/AU729231B2/en not_active Ceased
- 1997-02-18 DE DE69734585T patent/DE69734585T2/de not_active Expired - Fee Related
- 1997-02-18 ES ES97906594T patent/ES2251734T3/es not_active Expired - Lifetime
- 1997-02-18 TR TR1998/01615T patent/TR199801615T2/xx unknown
- 1997-02-18 HR HR9607293.9A patent/HRP970092A2/hr not_active Application Discontinuation
- 1997-02-18 CZ CZ982667A patent/CZ266798A3/cs unknown
- 1997-02-18 HU HU9901112A patent/HUP9901112A3/hu unknown
- 1997-02-18 BR BR9707672A patent/BR9707672A/pt unknown
- 1997-02-18 EE EE9800257A patent/EE9800257A/xx unknown
- 1997-02-18 IL IL12554797A patent/IL125547A0/xx unknown
- 1997-02-18 EP EP97906594A patent/EP0904380B1/en not_active Expired - Lifetime
- 1997-02-18 SK SK1129-98A patent/SK112998A3/sk unknown
- 1997-02-18 PL PL97328730A patent/PL328730A1/xx unknown
- 1997-02-20 AR ARP970100684A patent/AR005930A1/es unknown
- 1997-02-21 ID IDP970514A patent/ID16021A/id unknown
- 1997-02-21 CO CO97009327A patent/CO4600706A1/es unknown
- 1997-02-21 PE PE1997000126A patent/PE43298A1/es not_active Application Discontinuation
-
1998
- 1998-07-30 IS IS4814A patent/IS4814A/is unknown
- 1998-08-21 YU YU35498A patent/YU35498A/sh unknown
- 1998-08-21 NO NO983876A patent/NO983876L/no not_active Application Discontinuation
- 1998-09-23 BG BG102784A patent/BG102784A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU729231B2 (en) | 2001-01-25 |
WO1997031115A2 (en) | 1997-08-28 |
NO983876L (no) | 1998-10-21 |
HRP970092A2 (en) | 1998-04-30 |
NO983876D0 (no) | 1998-08-21 |
DE69734585D1 (de) | 2005-12-15 |
AU2124697A (en) | 1997-09-10 |
HUP9901112A2 (hu) | 1999-07-28 |
DE69734585T2 (de) | 2006-08-10 |
NZ331161A (en) | 2000-03-27 |
JP2000505299A (ja) | 2000-05-09 |
YU35498A (sh) | 1999-07-28 |
EE9800257A (et) | 1999-02-15 |
ATE309366T1 (de) | 2005-11-15 |
IS4814A (is) | 1998-07-30 |
CN1216064A (zh) | 1999-05-05 |
EP0904380A2 (en) | 1999-03-31 |
PL328730A1 (en) | 1999-02-15 |
HUP9901112A3 (en) | 2001-06-28 |
EP0904380B1 (en) | 2005-11-09 |
KR19990087126A (ko) | 1999-12-15 |
CZ266798A3 (cs) | 1999-03-17 |
BG102784A (en) | 1999-05-31 |
ES2251734T3 (es) | 2006-05-01 |
TR199801615T2 (xx) | 1998-11-23 |
PE43298A1 (es) | 1998-08-29 |
IL125547A0 (en) | 1999-03-12 |
CO4600706A1 (es) | 1998-05-08 |
WO1997031115A3 (en) | 1997-10-09 |
SK112998A3 (en) | 2000-04-10 |
BR9707672A (pt) | 1999-04-13 |
ID16021A (id) | 1997-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR005930A1 (es) | Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn | |
DK0969862T3 (da) | Syntetisk HIV gag-gener | |
PT1212358E (pt) | Genes sinteticos de papilomavirus humano | |
AR007862A1 (es) | Vacuna bovina, su uso y kit de vacunación que la contiene. | |
ES2151506T3 (es) | Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos. | |
ATE296618T1 (de) | Rna krebsimpfstoff und verfahren zu dessen benutzung | |
WO2003059381A3 (en) | Immunogenic preparations and vaccines on the basis of mrna | |
AR046835A1 (es) | Expresion optimizada de l1 de hpv58 en levadura | |
CO5360638A1 (es) | Un cepillo de dientes con cerdas individualmente embebidas | |
ES2173314T3 (es) | Metodos y composiciones para la modificacion selectiva de acidos nucleicos. | |
CY1115102T1 (el) | Πολυπεπτιδια που εμπλεκονται στην ανοσοαποκριση | |
AR014181A1 (es) | Formulaciones de vacuna capaces de incrementar las inmunorespuestas a los antigenos t-independientes y secuencias de deoxiribo o ribonucleoticosincluidos en dichas formulaciones; metodo para inducir inmunorespuestas a dichos t antigenos o antigenos de polisacaridos conjugados | |
ES2070866T3 (es) | Vacunas recombinantes contra la coccidiosis. | |
ES2156641T3 (es) | Composiciones cosmeticas detergentes y utilizacion. | |
AR011527A1 (es) | Metodo para mejorar la eficiencia de la transformacion | |
AR024771A1 (es) | Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes | |
ES2194024T3 (es) | Una proteina de de superficie celular, denominada proteina rib, que confiere inmunidad a muchas cepas de estreptococos del grupo b; procedimiento para purificar la proteina, kit de reactivos y composicion farmaceutica. | |
ES2146214T3 (es) | Vacunas para actinobacillus pleuropneumoniae. | |
ES2192559T3 (es) | Vacuna para la proteccion de aves de corral contra la coccidiosis. | |
DE60106222D1 (de) | Herpesviren für die modulation einer immunantwort | |
ECSP972034A (es) | Genes sinteticos vih | |
ES2059305T3 (es) | Proteina del virus de la seudorrabia. | |
AR022662A1 (es) | Acidos nucleicos y proteinas del gen mhp3 de mycoplasma hyopneumoniae y sus usos | |
ES2166763T3 (es) | Inmunizacion parenteral contra rotavirus. | |
ES2132050T1 (es) | Proceso para separar diclorodifluorometano. |